Azacitidine and Venetoclax for Acute Myeloid Leukemia (AML)
This study is looking at whether a combination of two drugs, azacitidine and venetoclax, can effectively reduce or eliminate measurable residual disease (MRD) in people with acute myeloid leukemia (AML). MRD means there are still a small number of cancer cells left after initial treatment. You might be able to join if you are an adult (18 or older) with newly diagnosed AML who has already received standard chemotherapy and is planning to have an allogeneic hematopoietic stem cell transplant (HSCT), also known as a bone marrow transplant. The main goal is to see how many participants achieve MRD conversion (meaning the cancer cells are no longer detectable) after one year.
- Study design
- This study is an interventional trial with a planned enrollment of 30 participants.
- What's involved
- You would receive azacitidine daily for 7 days (given intravenously or under the skin) and venetoclax orally daily for 28 days.
- Compensation
- Not stated in the trial record.
- Follow-up
- The primary endpoint, MRD conversion, will be measured at 1 year.
AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.
A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)
At a glance
Conditions
Where it's being run
7 sites across 2 statesStudy leadership
- Eytan Stein, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
- Meira Yisraeli Salman, MD · PRINCIPAL_INVESTIGATOR · Memorial Sloan Kettering Cancer Center
Who to contact
Opens a ready-to-send draft in your own email app — review before sending.
Do you actually qualify for this trial?
Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.
Inclusion
What this trial measures
- rate of MRD conversion1 year
MRD status will be assessed from end-of-cycle bone marrow aspirate, in all patients. MRD will be assessed by flow cytometry (MFC) or by RT-qPCR in molecular patients. This is a dichotomous variable of positive versus negative MRD, with a pre-defined threshold as described above, of 0.1% for MFC or 0.01% in molecular patients .